百币精
--
Trump strikes again with a fierce move, a storm of drug tariffs is coming!
Trump has a new tactic, targeting drug tariffs, and a storm of drug tariffs is imminent. Once the tariffs on imported drugs are imposed, the cost of affordable drugs purchased from India will rise, and drug prices are bound to increase.
Indian and Swiss pharmaceutical companies will be the first to suffer. As a major manufacturer of generic drugs, India supplies 70% of the generic drugs to the U.S., and the order volume will significantly decline after the tariffs are imposed. Leading pharmaceutical companies in Switzerland, such as Novartis and Roche, will also face high tariffs on their cancer and diabetes medications, raising the procurement costs for U.S. hospitals.
American citizens will also suffer, with prices for insulin, cancer drugs, and others expected to rise by 30%, causing chronic disease patients to spend significantly more each month. Although Trump proposed that pharmaceutical companies relocating back to the U.S. could be tax-exempt, building factories takes a long time and cannot solve the urgent problem.
What is the purpose of Trump's actions? Is it to divert the domestic conflict of drug abuse, to attract votes from the Rust Belt, or to suppress the impact of Indian and Chinese generics on American pharmaceutical companies? This is worth pondering.
Ordinary people should keep three points in mind: first, Chinese Americans should quickly stock up on chronic disease medications, as there may be shortages and price increases starting in April; second, be wary of black market low-quality generics, as taking the wrong medication can be extremely harmful; third, pharmaceutical companies will not absorb the losses themselves, and the increased costs of drug prices will ultimately be borne by health insurance and patients.
Trump's maneuver has put Indian pharmaceutical companies and American patients in a difficult position, while pharmaceutical company shareholders may secretly rejoice. Where will this storm lead? We will wait and see.
Trump has a new tactic, targeting drug tariffs, and a storm of drug tariffs is imminent. Once the tariffs on imported drugs are imposed, the cost of affordable drugs purchased from India will rise, and drug prices are bound to increase.
Indian and Swiss pharmaceutical companies will be the first to suffer. As a major manufacturer of generic drugs, India supplies 70% of the generic drugs to the U.S., and the order volume will significantly decline after the tariffs are imposed. Leading pharmaceutical companies in Switzerland, such as Novartis and Roche, will also face high tariffs on their cancer and diabetes medications, raising the procurement costs for U.S. hospitals.
American citizens will also suffer, with prices for insulin, cancer drugs, and others expected to rise by 30%, causing chronic disease patients to spend significantly more each month. Although Trump proposed that pharmaceutical companies relocating back to the U.S. could be tax-exempt, building factories takes a long time and cannot solve the urgent problem.
What is the purpose of Trump's actions? Is it to divert the domestic conflict of drug abuse, to attract votes from the Rust Belt, or to suppress the impact of Indian and Chinese generics on American pharmaceutical companies? This is worth pondering.
Ordinary people should keep three points in mind: first, Chinese Americans should quickly stock up on chronic disease medications, as there may be shortages and price increases starting in April; second, be wary of black market low-quality generics, as taking the wrong medication can be extremely harmful; third, pharmaceutical companies will not absorb the losses themselves, and the increased costs of drug prices will ultimately be borne by health insurance and patients.
Trump's maneuver has put Indian pharmaceutical companies and American patients in a difficult position, while pharmaceutical company shareholders may secretly rejoice. Where will this storm lead? We will wait and see.
Disclaimer: Includes third-party opinions. No financial advice. May include sponsored content. See T&Cs.
6
0